Stay Ahead of Compliance with Monthly Citation Updates


In your State Survey window and need a snapshot of your risks?

Survey Preparedness Report

One Time Fee
$79
  • Last 12 months of citation data in one tailored report
  • Pinpoint the tags driving penalties in facilities like yours
  • Jump to regulations and pathways used by surveyors
  • Access to your report within 2 hours of purchase
  • Easily share it with your team - no registration needed
Get Your Report Now →

Monthly citation updates straight to your inbox for ongoing preparation?

Monthly Citation Reports

$18.90 per month
  • Latest citation updates delivered monthly to your email
  • Citations organized by compliance areas
  • Shared automatically with your team, by area
  • Customizable for your state(s) of interest
  • Direct links to CMS documentation relevant parts
Learn more →

Save Hours of Work with AI-Powered Plan of Correction Writer


One-Time Fee

$49 per Plan of Correction
Volume discounts available – save up to 20%
  • Quickly search for approved POC from other facilities
  • Instant access
  • Intuitive interface
  • No recurring fees
  • Save hours of work
F0605
D

Failure to Monitor Psychotropic Medication Use and Necessity

Columbus, Ohio Survey Completed on 05-29-2025

Penalty

No penalty information released
tooltip icon
The penalty, as released by CMS, applies to the entire inspection this citation is part of, covering all citations and f-tags issued, not just this specific f-tag. For the complete original report, please refer to the 'Details' section.

Summary

The facility failed to ensure adequate behavioral monitoring and evaluation of psychotropic medication necessity for a resident with multiple complex diagnoses, including severe dementia with agitation and neurocognitive disorder with Lewy bodies. Upon review, the resident had physician orders for Seroquel, an antipsychotic medication, without any accompanying instructions for behavioral monitoring. There were no orders or documentation specifying behavioral monitoring, and the Medication Administration Record did not reflect any monitoring for effectiveness or adverse consequences related to the use of Seroquel. Progress notes from the period reviewed did not document any negative behaviors, and staff interviews confirmed the absence of recent behavioral issues. Further, the physician acknowledged that the Seroquel prescription was continued from a previous care setting and not based on recent behaviors, with no recent reports of behavioral issues or attempts at gradual dose reduction. Observations of the resident showed no negative behaviors, and staff interviews corroborated a decline in the resident's condition but no current behavioral concerns. The FDA guidelines for Seroquel indicate it is not approved for elderly patients with dementia-related psychosis, and the medication carries a black box warning for this population. Despite this, the facility did not implement or document behavioral monitoring to justify the ongoing use of the antipsychotic medication.

An unhandled error has occurred. Reload 🗙